> ## Content Index > Fetch the complete content index at: https://compounded.ghost.io/llms.txt > Use this file to discover other available public pages before exploring further. # Cellular Reprogramming Reached Its First Patients This Year. It Started in the Eye - URL: https://compounded.ghost.io/cellular-reprogramming-reached-its-first-patients-this-year-it-started-in-the-eye/ - Published: 2026-09-07T11:53:21.000Z - Updated: 2026-09-07T11:53:21.000Z - Author: Connor Hayes In June, a company working on epigenetic reprogramming dosed the first patient in a phase 1 trial of a therapy called ER-100, aimed at two optic nerve conditions: open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The FDA cleared the application earlier in the year, and the trial is the first time in humans that the specific approach behind a decade of laboratory rejuvenation headlines has been tested as a medicine. The approach is partial reprogramming, which uses three transcription factors, OCT4, SOX2 and KLF4, to push the pattern of gene expression in a cell back toward a younger configuration without erasing what that cell is. The distinction between resetting a cell partway and resetting it completely is the entire safety argument, and it is also why the first human test is happening in the eye rather than anywhere else. ### From the Lab to the Ledger Cells carry two layers of information. The genome is the sequence itself, largely fixed across a lifetime. The epigenome is the layer of chemical marks sitting on top of it, which decides which genes are read in which cell and at what level, and which drifts with age in patterns that can be measured. Reprogramming targets the second layer, on the reasoning that a cell losing function with age has not lost its instructions so much as lost track of which ones to follow. Push that reset all the way and a cell forgets what it is, which is how induced pluripotent stem cells are made, and uncontrolled it is also how tumors start. Partial reprogramming stops short of that point, using a controlled and time-limited burst of the factors. In laboratory work this restored function in aged tissue and, in the animal studies behind this trial, recovered vision in nonhuman primates with optic nerve damage. Every one of those results depended on controlling exposure, which is the practical engineering problem the field is actually solving. The eye is the logical first target for reasons that have little to do with aging as a theory. It is a small, immunologically privileged compartment where a therapy can be delivered locally rather than throughout the body, it can be imaged directly, vision can be measured with established instruments, and damage to retinal ganglion cells in these conditions is currently permanent. A trial there answers the safety question in a bounded space. The primary endpoints are safety and tolerability, with visual function as a secondary measure. That framing is the correct way to read this news: this is a first-in-human safety trial in a specific eye disease, not a test of whether anyone lives longer. ### Bio-Pipeline Ledger Partial epigenetic reprogramming as a laboratory technique: well established, with a decade of published work in cells and animals and consistent results on restored function in aged tissue. ER-100 in optic neuropathies: in a phase 1 trial with the first patient dosed in June, evaluating safety and tolerability first. Not approved, and no efficacy claim exists for it yet. Systemic, whole-body reprogramming: preclinical only. The delivery, dosing control, and cancer-risk questions that a local eye injection can sidestep are exactly the ones a systemic version would have to answer, and nothing has been cleared for that. Existing treatments for glaucoma: real and validated, including pressure-lowering drops and surgery, which slow further damage but do not restore function already lost. This is the gap the trial is aimed at. Epigenetic age tests sold direct to consumers: measure marks associated with biological aging, and are not a treatment or a validated basis for one. A number moving on such a test is not evidence that a tissue was restored. Clinics offering "cellular rejuvenation" or reprogramming-branded infusions: not supported by any controlled evidence. The first legitimate human trial of this mechanism began this year, in an eye clinic, under an FDA-cleared protocol. ### The Clinical Reality Check What is genuinely established is that a mechanism which spent ten years as a laboratory result has cleared regulatory review and entered human testing, with a design that reflects real caution about its known risk. That is a meaningful marker of progress, and it is a beginning rather than a result. What remains unknown is everything a phase 1 trial exists to find out. A safety readout in a small number of patients with a specific eye condition tells us little about whether controlled reprogramming can be delivered safely to other tissues, and nothing at all about lifespan. The honest reading is that the field now has one narrow test running where before it had none. The useful posture for anyone tracking this is patience with the timeline and firmness about the claims. Watch for the phase 1 safety readout and whether visual function moves at all, treat any commercial offer that borrows this vocabulary before those results exist as marketing, and keep the validated care for an actual eye condition on schedule in the meantime. ![](https://storage.ghost.io/c/93/20/932004ad-b501-4cef-8a02-28e1473c42cb/content/images/2026/09/epigenetic-reprogramming-first-human-trial-eye-2-photorealistic.jpg) ###